(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 May 2008 (15.05.2008)

PCT

(10) International Publication Number
WO 2008/057938 A1

(51) International Patent Classification:
C07D 471/08 (2006.01) *A61K 31/407* (2006.01)
A61P 25/00 (2006.01) *C07D 487/04* (2006.01)

(21) International Application Number:
PCT/US2007/083330

(22) International Filing Date:
1 November 2007 (01.11.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/856,079 2 November 2006 (02.11.2006) US

(71) Applicant *(for all designated States except US)*: **TARGACEPT, INC.** [US/US]; 200 East First Street, Suite 300, Winston-salem, North Carolina 27101-4165 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **MAZUROV, Anatoly** [UA/US]; 3704 Timberoak Drive, Greensboro, North Carolina 27410 (US). **MIAO, Lan** [US/US]; 226 March Ferry Road, Advance, North Carolina 27006 (US). **XIAO, Yun-de** [CN/US]; 2079 Waterford Village Drive, Clemmons, North Carolina 27012 (US). **HAMMOND, Philip, S.** [US/US]; 1162 Bradley Road, Pinnacle, North Carolina 27043 (US). **MILLER, Craig, H.** [US/US]; 1564 Sharon Road, Winston-salem, North Carolina 27103 (US). **AKIREDDY, Srinivisa, Rao** [IN/US]; 5829 Fox Point Circle, Winston-salem, North Carolina 27104 (US). **MURTHY, V. Srinivasa** [IN/US]; 595 Stonebridge Drive, Winston-salem, North Carolina 27104 (US). **WHITAKER, Regina C.** [US/US]; 3257 U.S. Hwy. 158, Mocksville, North Carolina 27028 (US). **BREINING, Scott R.** [US/US]; 2363 Rosewood Avenue, Winston-salem, North Carolina 27103 (US). **MELVIN, Matt, S.** [US/US]; 2074 Craig Street, Winston-salem, North Carolina 27103 (US).

(74) Agent: **MASSEY, JR., Carl B.**; Womble Carlyle Sandridge & Rice, PLLC, P.O. Box 7037, Atlanta, Georgia 30357 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(54) **Title:** NICOTINIC ACETYLCHOLINE RECEPTORSUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES

(57) **Abstract:** Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are amide compounds which can be prepared from certain heteroaryl carboxylic acids and certain diazabicycloalkanes. The compounds exhibit selectivity for, and bind with high affinity to, neuronal nicotinic receptors of the a4ß2 subtype in the central nervous system (CNS). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly CNS disorders. The compounds can: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects, and (iii) when employed in effective amounts, not result in appreciable adverse side effects (e.g. side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastrointestinal tract, and significant effects upon skeletal muscle).

WO 2008/057938 A1